Prices are updated after-hours
Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2021 - 06 - 03    symbols : NVS    save search
Novartis reports clinically relevant improvement in median overall survival data in final analysis of pivotal NETTER-1 study with targeted radioligand therapy Lutathera
Published: 2021-06-03 (Crawled : 22:00) - globenewswire.com
NVS | News | $92.53 -0.59% 670K twitter stocktwits trandingview |
Health Technology
 | | O: 0.55% H: 0.41% C: 0.0%
media therapy
Novartis 177Lu-PSMA-617 significantly improves overall survival and radiographic progression-free survival for men with metastatic castration-resistant prostate cancer in Phase III VISION study
Published: 2021-06-03 (Crawled : 17:00) - globenewswire.com
NVS | News | $92.53 -0.59% 670K twitter stocktwits trandingview |
Health Technology
 | | O: 0.06% H: 0.44% C: 0.42%
prostate cancer cancer
Gainers vs Losers
69% 31%

Top 10 Gainers
AGBA | $1.05 162.5% 100M twitter stocktwits trandingview |
Finance
ISPC | $0.4621 116.95% 15M twitter stocktwits trandingview |
Professional, Scientific, and T...
INVO | $1.515 99.34% 4.3M twitter stocktwits trandingview |
Health Technology
BPTH | $5.62 73.46% 75M twitter stocktwits trandingview |
Health Technology
TIRX | $0.8231 69.78% 54M twitter stocktwits trandingview |

XPON | $2.63 36.27% 8.4M twitter stocktwits trandingview |

PRTG | $0.299 35.17% 120K twitter stocktwits trandingview |
Mining, Quarrying, and Oil and ...
VTNR S | $1.26 28.68% 9.1M twitter stocktwits trandingview |
Industrial Services
SWVL | $9.64 27.35% 200K twitter stocktwits trandingview |
n/a
DFLI A | $0.7726 25.52% 4.3M twitter stocktwits trandingview |

Your saved searches
Save your searches and get alerts when important news are released.